END OF SUMMER SALE - 50% Off Site Wide

Ipamorelin

From $76.80

Shop

Ipamorelin · Research brief

How to Read Tesamorelin + Ipamorelin Blend COA — Explained

RP
Real Peptides Research TeamEditorial
Updated July 6, 20267 min read
58 WORDS

Short answer

Most researchers toss the Certificate of Analysis aside after verifying the product arrived. That's a mistake. A COA is the only objective proof that your tesamorelin + ipamorelin blend meets the purity and identity standards required for valid research outcomes. And reading it correctly means distinguishing between a compound that will perform as expected and one that won't.

Key takeaways

  • HPLC purity ≥95% confirms the peptide blend contains minimal synthesis byproducts, but doesn't verify molecular identity. Mass spectrometry and retention time do that.
  • Endotoxin levels above 1 EU/mg disqualify the peptide for mammalian cell work by triggering immune activation that confounds experimental results.
  • Molecular weight must be within ±0.5 Da of theoretical values (5135.89 Da for tesamorelin, 711.85 Da for ipamorelin) to confirm correct amino acid sequencing.
  • HPLC chromatograms with multiple large peaks indicate poor purification even if the reported purity percentage meets nominal thresholds.
  • Water content above 5% post-lyophilization skews reconstitution math. A vial labelled 5mg that contains 8% water actually contains 4.6mg peptide.
  • COA data is batch-specific and doesn't account for degradation during shipping or storage. Proper cold-chain handling after delivery is non-negotiable.

Most researchers toss the Certificate of Analysis aside after verifying the product arrived. That's a mistake. A COA is the only objective proof that your tesamorelin + ipamorelin blend meets the purity and identity standards required for valid research outcomes. And reading it correctly means distinguishing between a compound that will perform as expected and one that won't. A single misread data point. Endotoxin levels above threshold, peptide purity below 95%, or HPLC retention time drift. Can invalidate months of work without you realizing it.

We've guided hundreds of research teams through peptide verification protocols. The gap between doing it right and doing it wrong comes down to three things most guides never mention: which COA fields actually matter for dosing calculations, how to interpret HPLC chromatograms without a chemistry degree, and what endotoxin units mean in practical terms. This article covers those exact mechanics, the specific thresholds that separate research-grade from non-viable product, and how to read tesamorelin + ipamorelin blend COA data in under five minutes.

How do you verify a tesamorelin + ipamorelin blend meets research-grade standards before reconstitution?

Read the Certificate of Analysis (COA) by checking three critical fields: peptide purity percentage (must be ≥95% by HPLC), endotoxin level (must be <1 EU/mg for mammalian cell work), and molecular weight confirmation via mass spectrometry. These three data points confirm identity, concentration accuracy, and absence of bacterial contamination. The minimum quality thresholds required for reproducible research outcomes.

Most researchers assume a COA is a formality. Proof the lab tested the compound at some point. That's only half true. The COA verifies batch-specific quality at the time of synthesis, which means storage conditions, reconstitution technique, and handling after that point can all degrade purity and potency in ways the COA won't reflect. Reading the COA correctly tells you whether the peptide blend started viable. What happens after opening the vial is your protocol's responsibility. This piece covers how to decode purity percentages and endotoxin units, what HPLC retention times actually measure, and how to flag red-flag COA patterns that suggest synthesis errors or contamination.

Step 1: Verify Peptide Identity Through Molecular Weight and Retention Time

Before you evaluate purity, confirm you're working with the correct compound. The COA lists molecular weight (MW) for each peptide in the blend. Tesamorelin's theoretical MW is 5135.89 Da, ipamorelin's is 711.85 Da. Mass spectrometry data in the COA should show measured MW within ±0.5 Da of these values. If the measured MW for tesamorelin reads 5142 Da or 5129 Da, you're outside acceptable tolerance. The peptide sequence is likely truncated or modified during synthesis.

HPLC retention time is the second identity marker. Every peptide elutes from the chromatography column at a specific time based on its hydrophobicity and molecular structure. Tesamorelin typically elutes between 12–14 minutes depending on column type, ipamorelin between 8–10 minutes. If your COA shows tesamorelin eluting at 16 minutes, the chromatography conditions were non-standard or the peptide structure differs from the reference compound. Retention time drift of more than 1 minute from lot-to-lot batches suggests batch-to-batch inconsistency. A red flag for synthesis quality control.

Mass spec and HPLC retention time together confirm peptide identity. Purity percentage alone doesn't tell you whether the compound is the right molecule. Only how much of whatever was synthesized is present. We've seen COAs listing 98% purity for a peptide with the wrong molecular weight. High purity of the wrong compound is worthless.

Step 2: Interpret Purity Percentage and What the HPLC Trace Actually Shows

Peptide purity is measured by High-Performance Liquid Chromatography (HPLC) and reported as a percentage. Typically 95% or higher for research-grade material. This percentage represents the area under the main peak (your target peptide) divided by the total area of all peaks detected in the chromatogram. A 97% purity result means 97% of the detected peptide content is the target compound, with the remaining 3% representing truncated sequences, synthesis byproducts, or degradation fragments.

The HPLC chromatogram itself. The graph included on most COAs. Shows peaks corresponding to each detected compound over time. The tallest, sharpest peak is your target peptide. Smaller peaks before or after the main peak are impurities. If you see multiple large peaks of similar height, purity is likely below acceptable thresholds even if the COA reports a passing percentage. Multi-peak chromatograms suggest incomplete purification or peptide degradation.

Purity below 95% is generally unsuitable for mammalian cell work because the impurity fraction may include bioactive fragments or aggregates that interfere with receptor binding or cellular uptake. For tesamorelin + ipamorelin blends specifically, cross-contamination between the two peptides during synthesis can create hybrid fragments that bind growth hormone secretagogue receptors with unpredictable affinity. Skewing dose-response curves without obvious visual indicators in the chromatogram. When we review blend COAs, we verify that each peptide's HPLC trace shows a single dominant peak with no secondary peaks exceeding 2% of the main peak area.

Step 3: Decode Endotoxin Levels and Why the EU/mg Threshold Matters

Endotoxins are lipopolysaccharide fragments from bacterial cell walls that remain in peptide preparations even after purification. They trigger immune responses in mammalian cells at concentrations as low as 0.1 EU/mL. Well below levels that affect peptide purity percentage. The COA reports endotoxin content in Endotoxin Units per milligram (EU/mg). For research-grade peptides used in cell culture or animal models, the acceptable maximum is <1 EU/mg. Injectable-grade peptides require <0.5 EU/mg.

If your COA lists endotoxin at 2.3 EU/mg, the peptide is contaminated beyond safe use in most biological assays. Endotoxin contamination doesn't degrade peptide purity. HPLC won't detect it. But it will activate NFκB signaling pathways, elevate cytokine release, and confound any experiment measuring immune response, inflammation, or metabolic signaling. Tesamorelin and ipamorelin both modulate growth hormone release via hypothalamic pathways that overlap with immune signaling. Endotoxin contamination in these blends specifically can mask or amplify the peptides' GH-releasing effects depending on dose and exposure duration.

Endotoxin testing is performed via Limulus Amebocyte Lysate (LAL) assay. If the COA doesn't list endotoxin data, contact the supplier before use. Absence of endotoxin reporting is not the same as low endotoxin. It means the batch wasn't tested, which disqualifies it for any work requiring sterile or pyrogen-free conditions.

How to Read Tesamorelin + Ipamorelin Blend COA: Method Comparison

Verification Method What It Measures Acceptable Range What Failure Indicates
HPLC Purity (%) Percentage of target peptide vs impurities ≥95% for each peptide Incomplete purification, degradation, or synthesis error
Mass Spectrometry (MW) Molecular weight confirmation ±0.5 Da from theoretical MW Wrong peptide sequence, truncation, or post-synthesis modification
HPLC Retention Time Elution timing vs reference standard ±1 minute from reference Non-standard synthesis conditions or structural variance
Endotoxin (EU/mg) Bacterial lipopolysaccharide contamination <1 EU/mg (research), <0.5 EU/mg (injectable) Inadequate purification or sterile technique failure
Water Content (%) Residual moisture post-lyophilization <5% Improper lyophilization. Affects accurate dosing calculations

What If: Tesamorelin + Ipamorelin Blend COA Scenarios

What If the COA Shows 94% Purity for Tesamorelin but 97% for Ipamorelin?

Use the blend only if your protocol can tolerate slightly elevated impurity levels in the tesamorelin fraction. The 94% purity is below the standard 95% threshold, meaning up to 6% of the tesamorelin content is truncated peptides, aggregates, or synthesis byproducts. For dose-response studies or receptor binding assays, this impurity fraction introduces variability that may obscure treatment effects. For exploratory cell signaling work where precise dosing is less critical, 94% may be acceptable. But document the deviation and consider ordering a replacement batch for confirmatory experiments.

What If the Endotoxin Level Reads 1.2 EU/mg?

Do not use the peptide in any assay involving immune cells, cytokine measurement, or inflammatory pathway analysis. Endotoxin at 1.2 EU/mg is above the <1 EU/mg research-grade threshold and will activate Toll-like receptor 4 (TLR4) signaling in macrophages, dendritic cells, and endothelial cells. Elevating baseline cytokine production and skewing any readout that depends on immune quiescence. Request a replacement batch with verified endotoxin <0.5 EU/mg, or limit use to non-immune assays like receptor binding studies in HEK293 cells, which lack functional TLR4.

What If the Molecular Weight for Ipamorelin Reads 715 Da Instead of 711.85 Da?

The 3+ Da deviation exceeds acceptable tolerance and suggests the peptide sequence is incorrect. Likely an extra amino acid, incomplete deprotection during synthesis, or a side-chain modification. Do not use this batch. Ipamorelin's pentapeptide sequence (Aib-His-D-2-Nal-D-Phe-Lys-NH2) is highly specific for ghrelin receptor (GHSR1a) binding, and even single-residue changes abolish or invert agonist activity. A peptide with MW 715 Da is not ipamorelin regardless of what the label says. It's a synthesis error that should trigger a full batch rejection and replacement request.

What If No HPLC Chromatogram Is Included, Only a Purity Percentage?

Request the full chromatogram from the supplier before use. A purity percentage without the supporting chromatogram is unverifiable. You can't assess peak shape, retention time consistency, or the presence of secondary impurity peaks. Reputable peptide suppliers include chromatograms as standard COA documentation. If the supplier refuses to provide it, the reported purity is not trustworthy. We've encountered cases where reported 98% purity was later revealed to include multiple co-eluting peaks that the supplier combined into one

Build a pack

Researching more than one compound?

Build a multi-vial pack and the discount applies automatically as you add doses.

Start a pack

Questions

HPLC purity represents the percentage of the target peptide relative to all detected peptide content in the sample, calculated as the area under the main chromatography peak divided by total peak area. A 97% purity result means 97% of the peptide material is the correct target sequence, with the remaining 3% being truncated fragments, synthesis byproducts, or aggregates. For research-grade peptides, purity should be ≥95% for each peptide in the blend — lower purity introduces impurities that can interfere with receptor binding or cellular assays.
Compare the measured molecular weight from mass spectrometry to the theoretical MW for each peptide — tesamorelin should be 5135.89 Da (±0.5 Da), ipamorelin should be 711.85 Da (±0.5 Da). If the measured value is outside this ±0.5 Da range, the peptide sequence is likely incorrect due to truncation, incomplete deprotection, or amino acid substitution during synthesis. Molecular weight confirmation is the primary identity test — purity percentage alone doesn’t tell you whether you’re working with the right compound.
Endotoxin levels must be <1 EU/mg for research-grade peptides used in mammalian cell culture, and <0.5 EU/mg for injectable or in vivo work. Endotoxin above 1 EU/mg activates immune signaling pathways (via TLR4 receptors) that confound experimental results — particularly problematic for tesamorelin and ipamorelin studies because growth hormone release pathways overlap with immune-inflammation signaling. If the COA lists endotoxin above threshold or doesn't report it at all, request a replacement batch before use.
Use depends on your assay’s tolerance for impurities. The 94% purity peptide is below the standard ≥95% threshold, meaning up to 6% of that peptide content is non-target material — truncated sequences, aggregates, or synthesis byproducts. For precise dose-response studies or receptor binding assays, this variability can skew results. For exploratory signaling work where exact dosing is less critical, 94% may be acceptable. Document the deviation and consider ordering a higher-purity batch for confirmatory experiments.
Lyophilised peptides retain residual moisture — typically 2–5% by weight — that reduces the actual peptide mass below the labelled amount. A vial labelled 5mg with 7% water content contains only 4.65mg active peptide. If you reconstitute assuming 5mg, every dose administered is underdosed by 7%, which is enough to shift IC50 values or produce ‘no effect’ results in assays that should show clear activity. Always check the water content field on the COA and adjust reconstitution volume accordingly.
Multiple peaks indicate the sample contains significant impurities — synthesis byproducts, truncated peptides, or aggregates that weren’t removed during purification. A clean peptide chromatogram shows one tall, sharp peak (your target peptide) with no secondary peaks exceeding 2% of the main peak area. If you see multiple large peaks of similar height, purity is likely below acceptable thresholds even if the reported percentage meets nominal standards. Multi-peak chromatograms suggest incomplete purification or degradation and should trigger a batch rejection.
Retention time should be consistent within ±1 minute for the same peptide across batches when analysed under identical chromatography conditions. Tesamorelin typically elutes between 12–14 minutes, ipamorelin between 8–10 minutes depending on column type and mobile phase composition. Retention time drift beyond 1 minute suggests batch-to-batch synthesis inconsistency, non-standard chromatography conditions, or peptide structural variance. Large retention time shifts are a red flag for quality control problems and should be investigated before use.
Yes — COA data reflects quality at the time of synthesis and doesn’t account for degradation during storage. Peptides degrade over time even when stored correctly (lyophilised at −20°C), with purity declining 1–3% per year depending on sequence stability and storage conditions. If the COA is dated more than 6 months before your purchase date, request updated analytical testing or select a fresher batch. Recent COA data gives you a more accurate baseline for protocol work.
Request the chromatogram directly — it’s standard documentation for research-grade peptides. A purity percentage without the supporting chromatogram is unverifiable because you can’t assess peak shape, retention time, or secondary impurity peaks. If the supplier refuses to provide it, the reported purity is not trustworthy. Reputable peptide manufacturers include chromatograms as standard COA components because researchers who understand quality control will demand them. Unwillingness to provide full analytical data is a quality red flag.
High purity confirms the peptide is free of major synthesis impurities, but it doesn’t guarantee biological activity — peptide aggregation, oxidation, or misfolding can occur during lyophilisation or storage without reducing HPLC purity. Bioactivity must be confirmed through functional assays (receptor binding, cell signaling, or in vivo response) that test whether the peptide elicits the expected biological effect. COA data establishes baseline quality; functional validation establishes whether that quality translates to working compound in your specific protocol.

RESEARCH USE ONLY · NOT EVALUATED BY THE FDA

Shop Now